From Wikipedia, the free encyclopedia
Chemical compound
PF-3845
ATC code
Legal status
N-3-pyridinyl-4-([3-([5-(trifluoromethyl)-2-pyridinyl]oxy)phenyl]methyl)-1-piperidinecarboxamide
CAS Number
PubChem
CID
ChemSpider
UNII
CompTox Dashboard (
EPA )
Formula C 24 H 23 F 3 N 4 O 2
Molar mass 456.469 g·mol−1 3D model (
JSmol )
O=C(NC1=CN=CC=C1)N(CC2)CCC2CC3=CC=CC(OC4=NC=C(C(F)(F)F)C=C4)=C3
InChI=1S/C24H23F3N4O2/c25-24(26,27)19-6-7-22(29-15-19)33-21-5-1-3-18(14-21)13-17-8-11-31(12-9-17)23(32)30-20-4-2-10-28-16-20/h1-7,10,14-17H,8-9,11-13H2,(H,30,32)
Key:NBOJHRYUGLRASX-UHFFFAOYSA-N
PF-3845 is a selective
inhibitor of
fatty acid amide hydrolase .
[1] It results in increased levels of
anandamide and results in
cannabinoid
receptor -based effects. It has
anti-inflammatory action in
mice
colitis models.
Antidiarrheal and
antinociceptive effects were also seen in mouse models of pain.
[2]
A 2017 study published in the Journal of Psychiatry and Neuroscience found that PF-3845 exerts rapid and long-lasting anti-anxiety effects in mice exposed acutely to stress or chronically to the stress hormone corticosterone.
[3]
References
^ Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, et al. (April 2009).
"Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain" . Chemistry & Biology . 16 (4): 411–20.
doi :
10.1016/j.chembiol.2009.02.013 .
PMC
2692831 .
PMID
19389627 .
^ Fichna J, Sałaga M, Stuart J, Saur D, Sobczak M, Zatorski H, et al. (April 2014).
"Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides" . Neurogastroenterology and Motility . 26 (4): 470–81.
doi :
10.1111/nmo.12272 .
PMID
24460851 .
S2CID
2473356 .
^ Duan T, Gu N, Wang Y, Wang F, Zhu J, Fang Y, et al. (June 2017).
"Fatty acid amide hydrolase inhibitors produce rapid anti-anxiety responses through amygdala long-term depression in male rodents" . Journal of Psychiatry & Neuroscience . 42 (4): 230–241.
doi :
10.1503/jpn.160116 .
PMC
5487270 .
PMID
28234213 .
Receptor (
ligands )
CB1 Tooltip Cannabinoid receptor type 1
Agonists(abridged,
full list ) Inverse agonists Antagonists
CB2 Tooltip Cannabinoid receptor type 2
Agonists
2-AG
2-AGE (noladin ether)
3,3'-Diindolylmethane
4-O-Methylhonokiol
α-Amyrin · β-Amyrin
A-796,260
A-834,735
A-836,339
AM-1172
AM-1221
AM-1235
AM-1241
AM-2232
Anandamide
AZ-11713908
Cannabinol
Caryophyllene
CB-13
CBS-0550
CP 55,940
GW-405,833 (L-768,242)
GW-842,166X
HU-308
JTE 7-31
JWH-007
JWH-015
JWH-018
JWH-73
JWH-133
L-759,633
L-759,656
Lenabasum (anabasum)
Magnolol
MDA-19
Nabitan
NADA
Olorinab (APD-371)
PF-03550096
S-444,823
SER-601
Serinolamide A
UR-144
Tedalinab
THC (dronabinol)
THCV
Tetrahydromagnolol
Virodhamine
Antagonists
NAGly (
GPR18 )
GPR55
GPR119
Transporter (
modulators )
eCBTs Tooltip Endocannabinoid transporter
Enzyme (
modulators )
Others
Others:
2-PG (directly potentiates activity of 2-AG at CB1 receptor)
ARN-272 (FAAH-like anandamide transporter inhibitor)